MAPS (Multidisciplinary Association for Psychedelic Studies) is an independent nonprofit founded in 1986 by Rick Doblin that funds and advocates for psychedelic research, particularly MDMA-assisted therapy for PTSD and psilocybin studies. Its clinical research has advanced significantly, though the FDA's 2024 rejection of MDMA therapy citing study design concerns and the organization's advocacy mission blurring with research activities warrant careful distinction between its institutional output and promotional claims.